A recent Phase 1 clinical trial (NCT02359565) demonstrated that pediatric patients with hypermutated high-grade gliomas and mismatch repair deficiency can significantly benefit from treatment with immune checkpoint inhibitors, particularly through the use of a PD-1 inhibitor [70]. The gene discussed is PDCD1; the disease is mismatch repair cancer syndrome 1.